Sulfadiazine

Structural formula
General
Surname	Sulfadiazine
other names	4-Amino- N - (pyrimidin-2-yl) benzene sulfonamide ( IUPAC ); N1- (pyrimidin-2-yl) sulfanilamide; Sulfapyrimidine;
Molecular formula	C 10 H 10 N 4 O 2 S
Brief description	Crystalline, white to yellowish white or light pink powder
External identifiers / databases
EC number	200-685-8
ECHA InfoCard	100,000,623
PubChem	5215
ChemSpider	5026
DrugBank	DB00359
Wikidata	Q2555060
Drug information
ATC code	J01 EC02 , Q J01EQ10
Drug class	Sulfonamide
properties
Molar mass	250.28 g mol −1
Physical state	Firmly
Melting point	252 to 256 ° C
solubility	Practically insoluble in water, sparingly soluble in acetone , very sparingly soluble in ethanol 96%, soluble in alkali hydroxide solutions and dilute mineral acids.
safety instructions
	Please note the exemption from the labeling requirement for drugs, medical devices, cosmetics, food and animal feed
H and P phrases	H: 302-315-317-319-334-335
	P: 261-280-284-304 + 340-342 + 311
	As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions .

Sulfadiazine is an antiparasitic and bacteriostatic effective drug from the group of the sulfonamides . There it is one of the pyrimidine sulfonamides that were launched on the market from around 1946. It is effective orally, is rapidly absorbed in the gastrointestinal tract and, with a plasma half-life of 8 to 17 hours, is one of the moderately effective sulfonamides.

Sulfadiazine is indicated for the treatment of toxoplasmosis in humans in combination with pyrimethamine . The effect arises from the structural relationship with p -aminobenzoic acid and the resulting inhibition of the folic acid synthesis of the pathogens. The occurrence of Stevens-Johnson syndrome (SJS) and agranulocytosis have been observed as very rare, serious side effects .

The water-soluble sulfadiazine sodium is only suitable for parenteral administration. An insoluble form is silver sulfadiazine , which is used in local wound treatment.

Trade names

Debenal (hist.), Sulfadiazin-Heyl (D)

Individual evidence

↑ ^a ^b European Pharmacopoeia 9.0 , 2016, p. 3673.
↑ Entry on sulfadiazine. In: Römpp Online . Georg Thieme Verlag, accessed on April 10, 2020.
↑ ^a ^b Data sheet sulfadiazines ≥99.0% from Sigma-Aldrich , accessed on April 12, 2020 ( PDF ).
^ Harry Auterhoff : Textbook of Pharmaceutical Chemistry , 9th edition 1977, WVG Stuttgart. P. 464.
↑ ^a ^b G. Geisslinger et al .: Mutschler drug effects . 11th edition. WVG, Stuttgart 2019, p. 1019 f.
↑ ^a ^b Specialist information Sulfadiazin-Heyl 500 mg tablets , Heyl Chem.-pharm. Factory. As of December 2016.
↑ External identifiers or database links for sulfadiazine sodium : CAS number: 547-32-0, EC number: 208-919-0, ECHA InfoCard: 100.008.109 , PubChem : 15899898 , ChemSpider : 10565 , Wikidata : Q27269521 .

[EP9.0-1] European Pharmacopoeia 9.0 , 2016, p. 3673.

[römpp-2] Entry on sulfadiazine. In: Römpp Online . Georg Thieme Verlag, accessed on April 10, 2020.

[Sigma-3] Data sheet sulfadiazines ≥99.0% from Sigma-Aldrich , accessed on April 12, 2020 ( PDF ).

[auterhoff-4] Harry Auterhoff : Textbook of Pharmaceutical Chemistry , 9th edition 1977, WVG Stuttgart. P. 464.

[mutsch-5] G. Geisslinger et al .: Mutschler drug effects . 11th edition. WVG, Stuttgart 2019, p. 1019 f.

[heyl-6] Specialist information Sulfadiazin-Heyl 500 mg tablets , Heyl Chem.-pharm. Factory. As of December 2016.

[7] External identifiers or database links for sulfadiazine sodium : CAS number: 547-32-0, EC number: 208-919-0, ECHA InfoCard: 100.008.109 , PubChem : 15899898 , ChemSpider : 10565 , Wikidata : Q27269521 .